|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SUCLG2 |
Gene summary for SUCLG2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SUCLG2 | Gene ID | 8801 |
| Gene name | succinate-CoA ligase GDP-forming subunit beta | |
| Gene Alias | G-SCS | |
| Cytomap | 3p14.1 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q96I99 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8801 | SUCLG2 | P130T-E | Human | Esophagus | ESCC | 1.77e-26 | 6.11e-01 | 0.1676 |
| 8801 | SUCLG2 | NAFLD1 | Human | Liver | NAFLD | 4.91e-13 | 1.16e+00 | -0.04 |
| 8801 | SUCLG2 | S43 | Human | Liver | Cirrhotic | 1.62e-08 | -1.54e-01 | -0.0187 |
| 8801 | SUCLG2 | HCC1_Meng | Human | Liver | HCC | 1.59e-74 | -1.50e-01 | 0.0246 |
| 8801 | SUCLG2 | HCC2_Meng | Human | Liver | HCC | 3.75e-32 | -1.65e-01 | 0.0107 |
| 8801 | SUCLG2 | cirrhotic1 | Human | Liver | Cirrhotic | 1.31e-06 | -2.44e-01 | 0.0202 |
| 8801 | SUCLG2 | cirrhotic2 | Human | Liver | Cirrhotic | 8.21e-14 | 6.57e-02 | 0.0201 |
| 8801 | SUCLG2 | cirrhotic3 | Human | Liver | Cirrhotic | 7.78e-07 | -1.82e-01 | 0.0215 |
| 8801 | SUCLG2 | HCC1 | Human | Liver | HCC | 5.93e-07 | 2.97e+00 | 0.5336 |
| 8801 | SUCLG2 | HCC2 | Human | Liver | HCC | 7.06e-15 | 3.18e+00 | 0.5341 |
| 8801 | SUCLG2 | Pt13.a | Human | Liver | HCC | 4.30e-02 | -2.12e-01 | 0.021 |
| 8801 | SUCLG2 | Pt13.b | Human | Liver | HCC | 5.22e-20 | -7.89e-03 | 0.0251 |
| 8801 | SUCLG2 | Pt14.b | Human | Liver | HCC | 4.19e-10 | 1.72e-01 | 0.018 |
| 8801 | SUCLG2 | S027 | Human | Liver | HCC | 2.40e-04 | 8.57e-01 | 0.2446 |
| 8801 | SUCLG2 | S028 | Human | Liver | HCC | 2.02e-24 | 1.44e+00 | 0.2503 |
| 8801 | SUCLG2 | S029 | Human | Liver | HCC | 8.09e-24 | 1.66e+00 | 0.2581 |
| 8801 | SUCLG2 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 3.69e-02 | 1.62e-01 | -0.1408 |
| 8801 | SUCLG2 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.33e-13 | 6.44e-01 | -0.2116 |
| 8801 | SUCLG2 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 4.73e-07 | 5.13e-01 | -0.1941 |
| 8801 | SUCLG2 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.01e-03 | 3.62e-01 | -0.2107 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
| GO:0009060 | Colorectum | AD | aerobic respiration | 108/3918 | 189/18723 | 9.14e-28 | 1.43e-24 | 108 |
| GO:0045333 | Colorectum | AD | cellular respiration | 119/3918 | 230/18723 | 3.21e-25 | 4.02e-22 | 119 |
| GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
| GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
| GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
| GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
| GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
| GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
| GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
| GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
| GO:0006099 | Colorectum | AD | tricarboxylic acid cycle | 19/3918 | 30/18723 | 5.82e-07 | 2.09e-05 | 19 |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:0043648 | Colorectum | AD | dicarboxylic acid metabolic process | 34/3918 | 96/18723 | 7.22e-04 | 7.28e-03 | 34 |
| GO:0033865 | Colorectum | AD | nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| GO:0033875 | Colorectum | AD | ribonucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| GO:0034032 | Colorectum | AD | purine nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| GO:00090602 | Colorectum | MSS | aerobic respiration | 98/3467 | 189/18723 | 3.35e-25 | 1.05e-21 | 98 |
| GO:00060912 | Colorectum | MSS | generation of precursor metabolites and energy | 186/3467 | 490/18723 | 1.14e-24 | 2.15e-21 | 186 |
| GO:00453332 | Colorectum | MSS | cellular respiration | 107/3467 | 230/18723 | 1.64e-22 | 2.05e-19 | 107 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
| hsa00020 | Colorectum | AD | Citrate cycle (TCA cycle) | 20/2092 | 30/8465 | 1.43e-06 | 1.77e-05 | 1.13e-05 | 20 |
| hsa00640 | Colorectum | AD | Propanoate metabolism | 18/2092 | 32/8465 | 1.33e-04 | 1.11e-03 | 7.08e-04 | 18 |
| hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
| hsa000201 | Colorectum | AD | Citrate cycle (TCA cycle) | 20/2092 | 30/8465 | 1.43e-06 | 1.77e-05 | 1.13e-05 | 20 |
| hsa006401 | Colorectum | AD | Propanoate metabolism | 18/2092 | 32/8465 | 1.33e-04 | 1.11e-03 | 7.08e-04 | 18 |
| hsa012004 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
| hsa000204 | Colorectum | MSS | Citrate cycle (TCA cycle) | 16/1875 | 30/8465 | 1.84e-04 | 1.47e-03 | 9.00e-04 | 16 |
| hsa006404 | Colorectum | MSS | Propanoate metabolism | 15/1875 | 32/8465 | 1.68e-03 | 9.05e-03 | 5.55e-03 | 15 |
| hsa012005 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
| hsa000205 | Colorectum | MSS | Citrate cycle (TCA cycle) | 16/1875 | 30/8465 | 1.84e-04 | 1.47e-03 | 9.00e-04 | 16 |
| hsa006405 | Colorectum | MSS | Propanoate metabolism | 15/1875 | 32/8465 | 1.68e-03 | 9.05e-03 | 5.55e-03 | 15 |
| hsa012006 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
| hsa006406 | Colorectum | FAP | Propanoate metabolism | 15/1404 | 32/8465 | 6.21e-05 | 6.10e-04 | 3.71e-04 | 15 |
| hsa000206 | Colorectum | FAP | Citrate cycle (TCA cycle) | 14/1404 | 30/8465 | 1.16e-04 | 1.02e-03 | 6.21e-04 | 14 |
| hsa012007 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
| hsa006407 | Colorectum | FAP | Propanoate metabolism | 15/1404 | 32/8465 | 6.21e-05 | 6.10e-04 | 3.71e-04 | 15 |
| hsa000207 | Colorectum | FAP | Citrate cycle (TCA cycle) | 14/1404 | 30/8465 | 1.16e-04 | 1.02e-03 | 6.21e-04 | 14 |
| hsa012008 | Colorectum | CRC | Carbon metabolism | 28/1091 | 115/8465 | 5.43e-04 | 5.48e-03 | 3.72e-03 | 28 |
| hsa000208 | Colorectum | CRC | Citrate cycle (TCA cycle) | 11/1091 | 30/8465 | 8.16e-04 | 6.99e-03 | 4.74e-03 | 11 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SUCLG2 | SNV | Missense_Mutation | novel | c.806N>A | p.Arg269Gln | p.R269Q | Q96I99 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| SUCLG2 | deletion | Frame_Shift_Del | novel | c.503_519delNNNNNNNNNNNNNNNNN | p.Val168GlyfsTer5 | p.V168Gfs*5 | Q96I99 | protein_coding | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SUCLG2 | deletion | Frame_Shift_Del | novel | c.279delN | p.Gly94ValfsTer7 | p.G94Vfs*7 | Q96I99 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SUCLG2 | SNV | Missense_Mutation | c.616C>T | p.Arg206Trp | p.R206W | Q96I99 | protein_coding | deleterious(0.02) | benign(0.031) | TCGA-MA-AA3W-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SUCLG2 | SNV | Missense_Mutation | c.494C>T | p.Pro165Leu | p.P165L | Q96I99 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AA-3488-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
| SUCLG2 | SNV | Missense_Mutation | novel | c.905N>C | p.Asn302Thr | p.N302T | Q96I99 | protein_coding | tolerated(0.09) | possibly_damaging(0.854) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SUCLG2 | SNV | Missense_Mutation | c.1007N>A | p.Gly336Asp | p.G336D | Q96I99 | protein_coding | deleterious(0) | possibly_damaging(0.76) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |
| SUCLG2 | SNV | Missense_Mutation | rs149334981 | c.208N>A | p.Glu70Lys | p.E70K | Q96I99 | protein_coding | tolerated(0.62) | benign(0.009) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SUCLG2 | SNV | Missense_Mutation | novel | c.824N>A | p.Ala275Asp | p.A275D | Q96I99 | protein_coding | tolerated(0.25) | benign(0.007) | TCGA-A5-AB3J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| SUCLG2 | SNV | Missense_Mutation | c.407N>G | p.Lys136Arg | p.K136R | Q96I99 | protein_coding | tolerated(0.32) | benign(0.005) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |